Mounjaro vs Wegovy: what switching GLP-1s actually means

What did @sharmys.mounjaro.j actually say?

The short version: she switched from Wegovy (semaglutide) to Mounjaro (tirzepatide) after six weeks of weight gain, increased cravings, and what she describes as a complete loss of appetite suppression. Her headline claim is that Mounjaro "affects two hormones or something in your head" while Wegovy "only does one," which she says explains Mounjaro's "lower success rate" for Wegovy.

She also reports losing "just shy of five stone" over 17 months on Mounjaro previously, describes a return of food cravings she hadn't experienced in over a year, and ties the craving resurgence specifically to switching medications. She's transparent about confounding factors: a recent hospitalisation for a gastrointestinal illness, limited mobility due to chronic pain, and some dietary lapses involving Costco cookies and jelly sweets. Credit where it's due, she's more self-aware than most GLP-1 content on TikTok.

Does the science back this up?

The dual-receptor mechanism she's describing is real, and the outcome data does favour tirzepatide. Tirzepatide activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Semaglutide only activates GLP-1. That distinction matters clinically.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15mg produced mean weight loss of 20.9% over 72 weeks in people without diabetes. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced 14.9% mean weight loss over 68 weeks. A 2023 network meta-analysis by Shi et al. in the International Journal of Obesity confirmed tirzepatide outperforms semaglutide for weight reduction across comparable timeframes. So her core point that Mounjaro tends to produce greater weight loss is backed by evidence. Where she stumbles is the mechanism explanation, which we'll get to.

On the craving side: GIP receptor agonism appears to influence reward pathways and dopamine signalling in the brain, which may explain differential appetite and craving suppression between the two drugs. A 2023 preclinical review by Kern et al. in Obesity Reviews noted GIP receptors in mesolimbic regions may modulate hedonic eating. This is still an emerging area, but it's plausible.

What did they get wrong (or right)?

She got the receptor count right but the interpretation slightly off. She says Wegovy has a "less lower success rate," which is grammatically confusing but directionally accurate: semaglutide does produce less average weight loss than tirzepatide in trials. However, individual response varies enormously. Six weeks is also a short window to judge efficacy, and her hospitalisation and dietary changes are significant confounders she herself acknowledges but doesn't fully weight.

Her framing that something is "misfiring with that GLP-1" because Wegovy only hits one receptor is simplified but not wrong in spirit. The problem is she presents this as settled science when the GIP-appetite-reward mechanism is still being studied in humans. It's a reasonable hypothesis, not a proven explanation for her individual response.

What she gets genuinely right: her previous five-stone loss on Mounjaro is consistent with the drug's clinical profile. Her observation that cravings returned specifically after switching, and not before, is clinically interesting even if anecdotal. Individual pharmacological responses to GLP-1 and dual-agonist drugs do differ, and her experience isn't unusual in GLP-1 clinical communities.

What should you actually know?

If you're considering switching between semaglutide and tirzepatide, or starting either, a few things the algorithm won't tell you. First, population averages from trials don't predict your individual response. Second, six weeks on a new GLP-1 medication, especially at a low titration dose, is not enough time to assess full efficacy. Most protocols titrate over months before drawing conclusions.

Third, non-pharmacological factors matter more than GLP-1 content usually admits. Her hospitalisation, altered gut motility post-illness, and dietary environment changes (hello, Costco cookies on the counter) are all legitimate variables. A medication switch may or may not resolve those.

Finally, neither Wegovy nor Mounjaro is a permanent fix in isolation. The 2022 STEP 4 trial (Rubino et al., NEJM) showed that stopping semaglutide reversed most weight loss within a year. Tirzepatide data from SURMOUNT-4 shows similar rebound. These are long-term medications for a chronic condition, not a six-week course.

If your current GLP-1 isn't working after proper titration, talking to a prescriber about switching is legitimate. Crowdsourcing the decision on TikTok, less so.